目的 探討采取回生口服液聯(lián)合托泊替康治療卵巢癌的臨床效果。方法 選取河南省人民醫(yī)院于2016年2月—2017年2月收治的卵巢癌患者121例，隨機(jī)分成對(duì)照組（60例）和治療組（61例）。對(duì)照組患者靜脈滴注注射用鹽酸托泊替康，2.0 mg/m²，1次/d，21 d為1個(gè)療程，分別在每個(gè)療程的第1、8、15天進(jìn)行治療。治療組患者在對(duì)照組基礎(chǔ)上口服回生口服液，10 mL/次，3次/d，21 d為1個(gè)療程。兩組患者均連續(xù)治療3個(gè)療程。觀察兩組患者臨床療效，比較治療前后兩組患者KPS和QDL評(píng)分，癌抗原125（CA-125）、IL-6和人附睪分泌蛋白4（HE4）水平及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組客觀緩解率為43.33%，疾病控制率為65.00%，均分別顯著低于治療組的60.66%和83.61%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者KPS評(píng)分和QDL評(píng)分均顯著升高（P<0.05）；且治療組患者各評(píng)分比對(duì)照組升高的更為明顯（P<0.05）。治療后，兩組患者CA-125水平明顯升高，IL-6和HE4水平明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者CA-125、IL-6和HE4水平明顯優(yōu)于對(duì)照組（P<0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率為47.54%，顯著高于對(duì)照組的25.00%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 回生口服液聯(lián)合托泊替康治療卵巢癌患者臨床療效顯著，不良反應(yīng)發(fā)生率低，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Huisheng Oral Liquid combined with topotecan in treatment of ovarian cancer. Methods Patients (121 cases) with ovarian cancer in Henan Province People's Hospital from February 2016 to February 2017 were randomly divided into control (60 cases) and treatment (61 cases) based. Patients in the control group were iv administered with Topotecan Hydrochloride for injection, 2.0 mg/m², once daily, 21 d as a course of treatment, and they were treated on the 1st, 8th, and 15th day. Patients in the treatment group were po administered with Huisheng Oral Liquid on the basis of the control group, 10 mL/time, three times daily, and 21 d as a course of treatment. Patients in two groups were treated for 3 courses of treatment. After treatment, the clinical efficacy was evaluated, and the KPS and QDL scores, the CA-125, IL-6 and HE4 levels, the adverse reactions in two groups before and after treatment was compared. Results After treatment, the objective remission rate and disease control rate in the control group were 43.33% and 65.00%, which were significantly lower than 60.66% and 83.61% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the KPS and QDL scores in two groups were significantly increased (P < 0.05). And the scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the CA-125 level in two groups was significantly increased, but IL-6 and HE4 levels were significantly decreased, and there were differences in the same group (P < 0.05). And the CA-125, IL-6 and HE4 levels in the treatment group were significantly better than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 47.54%, which was significantly higher than 25.00% in the control group, with significant difference between two groups (P < 0.05). Conclusion Huisheng Oral Liquid combined with topotecan has significant clinical efficacy in treatment of ovarian cancer with lower adverse reactions incidence, which has a certain clinical application value.